Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution
Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increases cellular edema due to repeated solution administration. We reviewed the clinical experiences on myocardial protection of a single perfusion with histidine-tryptophan-ketoglutarate (HTK) for high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. This retrospective study included 101 high-risk patients undergoing arterial switch operation between March 2001 and July 2012. We divided the cohort into two groups: HTK group, myocardial protection was carried out with one single perfusion with HTK solution; and St group, myocardial protection with conventional St. Thomas' crystalloid cardioplegic solution. The duration of cardiopulmonary bypass did not differ between the two groups. The mortality, morbidity, ICU stay, post-operative hospitalization time, and number of transfusions in HTK group were lower than those in St group (P<0.05). Univariate and multivariate analysis showed that HTK is a statistically significant independent predictor of decreased early mortality and morbidity (P<0.05). In conclusion, HTK solution seems to be an effective and safe alternative to St. Thomas' solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease.
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2016
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000600703 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0100-879X2016000600703 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0100-879X20160006007032019-03-25Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institutionLi,X.W.Lin,Y.Z.Lin,H.Huang,J.B.Tang,X.M.Long,X.M.Lu,W.J.Wen,Z.K.Liang,J.Li,D.Y.Zhao,X.F. Histidine-tryptophan-ketoglutarate Myocardial protection Cardiac surgery Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increases cellular edema due to repeated solution administration. We reviewed the clinical experiences on myocardial protection of a single perfusion with histidine-tryptophan-ketoglutarate (HTK) for high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. This retrospective study included 101 high-risk patients undergoing arterial switch operation between March 2001 and July 2012. We divided the cohort into two groups: HTK group, myocardial protection was carried out with one single perfusion with HTK solution; and St group, myocardial protection with conventional St. Thomas' crystalloid cardioplegic solution. The duration of cardiopulmonary bypass did not differ between the two groups. The mortality, morbidity, ICU stay, post-operative hospitalization time, and number of transfusions in HTK group were lower than those in St group (P<0.05). Univariate and multivariate analysis showed that HTK is a statistically significant independent predictor of decreased early mortality and morbidity (P<0.05). In conclusion, HTK solution seems to be an effective and safe alternative to St. Thomas' solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.49 n.6 20162016-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000600703en10.1590/1414-431x20165208 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Li,X.W. Lin,Y.Z. Lin,H. Huang,J.B. Tang,X.M. Long,X.M. Lu,W.J. Wen,Z.K. Liang,J. Li,D.Y. Zhao,X.F. |
spellingShingle |
Li,X.W. Lin,Y.Z. Lin,H. Huang,J.B. Tang,X.M. Long,X.M. Lu,W.J. Wen,Z.K. Liang,J. Li,D.Y. Zhao,X.F. Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution |
author_facet |
Li,X.W. Lin,Y.Z. Lin,H. Huang,J.B. Tang,X.M. Long,X.M. Lu,W.J. Wen,Z.K. Liang,J. Li,D.Y. Zhao,X.F. |
author_sort |
Li,X.W. |
title |
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution |
title_short |
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution |
title_full |
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution |
title_fullStr |
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution |
title_full_unstemmed |
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution |
title_sort |
histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution |
description |
Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increases cellular edema due to repeated solution administration. We reviewed the clinical experiences on myocardial protection of a single perfusion with histidine-tryptophan-ketoglutarate (HTK) for high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. This retrospective study included 101 high-risk patients undergoing arterial switch operation between March 2001 and July 2012. We divided the cohort into two groups: HTK group, myocardial protection was carried out with one single perfusion with HTK solution; and St group, myocardial protection with conventional St. Thomas' crystalloid cardioplegic solution. The duration of cardiopulmonary bypass did not differ between the two groups. The mortality, morbidity, ICU stay, post-operative hospitalization time, and number of transfusions in HTK group were lower than those in St group (P<0.05). Univariate and multivariate analysis showed that HTK is a statistically significant independent predictor of decreased early mortality and morbidity (P<0.05). In conclusion, HTK solution seems to be an effective and safe alternative to St. Thomas' solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease. |
publisher |
Associação Brasileira de Divulgação Científica |
publishDate |
2016 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000600703 |
work_keys_str_mv |
AT lixw histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT linyz histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT linh histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT huangjb histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT tangxm histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT longxm histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT luwj histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT wenzk histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT liangj histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT lidy histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution AT zhaoxf histidinetryptophanketoglutaratesolutiondecreasesmortalityandmorbidityinhighriskpatientswithseverepulmonaryarterialhypertensionassociatedwithcomplexcongenitalheartdiseasean11yearexperiencefromasingleinstitution |
_version_ |
1756391519415173120 |